Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice
- 246 Downloads
Acutely ill hospitalized medical patients remain at high thromboembolic risk for several weeks after discharge. Previous trials with extended-duration thromboprophylaxis using enoxaparin, apixaban, and rivaroxaban failed to achieve acceptable net clinical benefit, largely due to excess of major bleeding. Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio. The phase III APEX trial (N = 7513) compared a betrixaban 160 mg loading dose followed by 80 mg once daily for 35–42 days, with enoxaparin 40 mg once daily for 6–14 days; the betrixaban dose was reduced for renal impairment or a concomitant strong P-glycoprotein (P-gp) inhibitor. The primary efficacy endpoint of composite thrombotic events was not different between treatment arms in cohort 1 (d-dimer ≥ 2 × upper limit of normal). Subsequent exploratory analyses showed a statistically significant difference favoring betrixaban for symptomatic venous thromboembolism and net clinical benefit in the overall population. For the primary safety outcome, betrixaban did not significantly increase major bleeding compared with enoxaparin. Based on available data from the APEX trial and subanalyses, the use of betrixaban in patients similar to those enrolled in the APEX trial can reduce the risk of thromboembolic events without increasing the risk of major bleeding. Patients who may benefit more from betrixaban therapy include those with elevated d-dimer, history of venous thromboembolism, hospitalized for ischemic stroke, hospitalized for heart failure with N-terminal pro-B-type natriuretic peptide ≥ 1975 ng/L, or two or more VTE risk factors. Reduced-dose betrixaban does not appear to provide the same clinical utility as full-dose betrixaban.
Compliance with Ethical Standards
No funding was received for the preparation of this manuscript.
Conflict of Interest
Dr Miller declares no conflicts of interest. Dr Brenner declares no conflicts of interest.
- 2.Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94:750–9.Google Scholar
- 15.Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the international medical prevention registry on venous thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3:e001152. https://doi.org/10.1161/JAHA.114.001152.CrossRefGoogle Scholar
- 17.Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–51.Google Scholar
- 18.Huisman MV, Klok FA. Pharmacological properties of betrixaban. Eur Heart J Suppl. 2018;20(Suppl E):E1–2.Google Scholar
- 19.Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J. 2014;167(3):335–41. https://doi.org/10.1016/j.ahj.2013.11.006.CrossRefGoogle Scholar
- 20.Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Gibson CM, Hernandez AF, Gold A. Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J. 2015;169(1):186–7. https://doi.org/10.1016/j.ahj.2014.09.004.CrossRefGoogle Scholar
- 21.Chi G, Goldhaber SZ, Hull RD, Hernandez AF, Kerneis M, Al Khalfan F, Cohen AT, Harrington RA, Gibson CM. Thrombus burden of deep vein thrombosis and its association with thromboprophylaxis and d-dimer measurement: insights from the APEX trial. Thromb Haemost. 2017;117(12):2389–95. https://doi.org/10.1160/TH17-08-0538.CrossRefGoogle Scholar
- 22.Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. J Thromb Thrombolysis. 2018;45(1):1–8. https://doi.org/10.1007/s11239-017-1583-0.CrossRefGoogle Scholar
- 23.Chi G, Januzzi JL, Korjian S, Daaboul Y, Goldhaber SZ, Hernandez AF, Hull RD, Gold A, Cohen AT, Harrington RA, Gibson CM. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017;44(4):457–65. https://doi.org/10.1007/s11239-017-1552-7.CrossRefGoogle Scholar
- 24.Gibson CM, Nafee T, Yee MK, Chi G, Korjian S, Daaboul Y, AlKhalfan F, Kerneis M, Goldhaber SZ, Hull R, Hernandez AF, Cohen AT, Harrington RA. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018;198:84–90. https://doi.org/10.1016/j.ahj.2017.12.015.CrossRefGoogle Scholar
- 25.Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients: findings from the APEX trial (acute medically ill venous thromboembolism prevention with extended duration betrixaban trial). Circulation. 2018;137(1):91–4. https://doi.org/10.1161/CIRCULATIONAHA.117.031187.CrossRefGoogle Scholar
- 26.Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, APEX Investigators. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban). Circulation. 2017;135(7):648–55. https://doi.org/10.1161/circulationaha.116.025427.CrossRefGoogle Scholar
- 28.Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT, APEX Investigators. The safety and efficacy of full- versus reduced-dose betrixaban in the acute medically ill VTE (venous thromboembolism) prevention with extended-duration betrixaban (APEX) trial. Am Heart J. 2017;185:93–100. https://doi.org/10.1016/j.ahj.2016.12.004.CrossRefGoogle Scholar
- 29.Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA, APEX Investigators. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy. J Am Heart Assoc. 2017;6(7):e006015. https://doi.org/10.1161/jaha.117.006015.CrossRefGoogle Scholar
- 30.Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017;15(10):1913–22. https://doi.org/10.1111/jth.13783.CrossRefGoogle Scholar
- 32.Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.CrossRefGoogle Scholar
- 38.Bevyxxa® [package insert]. South San Francisco: Portola Pharmaceuticals, Inc; 2017.Google Scholar
- 39.Center for Drug Evaluation and Research. Approved drugs—FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. 23 June 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm. Accessed 2 Sept 2018.
- 43.Xarelto® [package insert]. Titusville: Janssen Pharmaceutical Inc; 2011.Google Scholar